Hi,
This is part of the CARIS report of my brothers tumour. We are looking into further drugs for him to take. Can anyone offer any advice from this information? I have 12 pages of results but unfortunately the Dr hasn't offered any advice!Thanks, Lisa
PAGE 2 of 12
Biomarker
|
Method
|
Result
|
EGFR
|
IHC
|
Positive
|
MGMT
|
Pyro SEQ
|
Methylated
|
PD-1 IHC
|
IHC
|
Positive
|
RRM1
|
IHC
|
Negative
|
Biomarker
|
Method
|
Result
|
TLE3
|
IHC
|
Positive
|
TOPO1
|
IHC
|
Positive
|
TS
|
IHC
|
Negative
|
One of the drawbacks of the CARIS Molecular Intelligence report is that many of the genes and markers they test for are predictive of response to chemotherapies like gemcitabine, taxanes, or other chemos that are rarely if ever used in brain tumors.
ReplyDeleteOf the markers above, the most relevant are EGFR and MGMT...and PD-1 if you can afford or get insurance coverage or join a trial for PD-1 inhibitors such as nivolumab and pembrolizumab.
Can you give us some background? When was he diagnosed, how old is he, what treatments has he had so far?
Was there strong staining for EGFR? In any case I'd recommend testing for the EGFRvIII mutation. Chloroquine could be a useful drug for EGFR+ or EGFR mutant GBM.
Hi Stephen, is the foundation report different to the Caris report? Would our oncologist know what to make of the report we have? So far he hasn't mentioned it even though he knew we were paying to have it done. Not sure it was $6000 well spent...
ReplyDeleteSee my brief summary of the Foundation and Caris reports on this page (down near the bottom):
Deletehttp://astrocytomaoptions.com/interpreting-pathology-reports/
The FoundationOne test sequences over 300 different cancer-related genes, and can detect mutations, and gene amplifications or homozygous (double) deletions. It doesn't do any other sort of testing (IHC, DNA methylation status etc.).
CARIS does all different kinds of testing, but on a much more limited number of genes/proteins. It is focused on genes/proteins related to chemosensitivity, but most of the chemos are never or rarely used for brain tumors (mostly due to inability to cross the blood-brain barrier).
FoundationOne is only covered by insurance providers in the United States (this is what I was told by a company rep).
If you email me the report I may be able to find additional actionable information.
Thanks Stephen I'll email you. Where do you find the time to respond to us all? You are very much appreciated! Lisa :)
Delete